Journal
PERSONALIZED MEDICINE
Volume 14, Issue 4, Pages 355-365Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pme-2017-0003
Keywords
EU funding; personalized medicine; policy development
Categories
Ask authors/readers for more resources
Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment and care. It helps to address the challenge of the aging of the population, an increase in chronic disease and increasing healthcare costs. The EU is developing policies to move toward PM. This is underpinned by a sustained and significant investment starting in 2010. So far, a total of (sic)3.2 billion has been invested in PM research across the medical innovation cycle 'from bench to bedside'. This investment has come from the research framework programs FP7 and Horizon 2020. About a third of the total investment has been made in the context of the Innovative Medicines Initiative, the largest public-private partnership in life sciences globally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available